Is Etrasimod a domestic or imported drug?

Etrasimod is an innovative S1P receptor modulator, mainly used to treat immune-mediated diseases such as moderately to severely active ulcerative colitis (UC). It regulates the migration of lymphocytes by acting on specific receptors in the immune system, thereby reducing the inflammatory response. Itramod's mechanism of action makes it a therapeutic drug with great potential, especially in the treatment of chronic inflammatory bowel disease and other immune-related diseases.

However, currently Etrasimod (Etrasimod) has not yet been launched in the Chinese market, nor has it been included in China's medical insurance directory. The drug is developed and produced by Pfizer, an American pharmaceutical company. As one of the world's leading pharmaceutical companies, Pfizer has launched the innovative drug Itrimod with its strong R&D background and rich clinical experience. However, as it is still in the clinical trial or regulatory approval stage, it is not currently officially available in China.

In China, there are currently no imported drugs for Itrimod, and patients who need to use the drug usually need to go through specific channels or participate in international clinical trials. Since there is no imported version of the drug in China, there are no domestic generics on the market. Although research on this drug is progressing rapidly in some regions around the world, the approval process for the Chinese market is still in its early stages, so we cannot yet foresee the specific launch time of this drug.

For the majority of patients, itridimod, as a potential therapeutic drug, may gradually gain attention in future clinical applications. As the clinical research and review process of itrimod progresses, patients can expect to see the drug launched in the Chinese market in the next few years.

Reference materials:https://www.drugs.com/mtm/etrasimod.html